===========================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: JULY 3, 2001
DATE OF EARLIEST EVENT REPORTED: JULY 2, 2001
ICN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 1-11397 33-0628076
(State or other (Commission File Number) (I.R.S. Employer
jurisdiction of Identification
incorporation or Number)
organization)
3300 HYLAND AVENUE
COSTA MESA, CALIFORNIA 92626
(Address of principal executive offices)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (714) 545-0100
Item 5. Other Events.
------------
On July 2, 2001, the registrant issued the press release filed as
Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
---------------------------------
Exhibit Description
------- -----------
99.1 Press Release issued July 2, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on behalf of
the undersigned hereunto duly authorized.
Dated: July 3, 2001
ICN PHARMACEUTICALS, INC.
By: /s/ David C. Watt
--------------------------------
David C. Watt
Executive Vice President,
General Counsel and
Corporate Secretary
EXHIBIT INDEX
Exhibit Description
------- -----------
99.1 Press Release issued July 2, 2001